Novo-ZymoGenetics: The Next Roche-Genentech?
Executive Summary
Novo Nordisk's decision to spin off ZymoGenetics in 2000 was 100% inspired by Roche's hands-off relationship with Genentech. The parent claims Zymo's R&D productivity has since increased; its recent ex-US deal with Bayer-Schering on recombinant thrombin proves that Zymo has certainly grown up and left home.
You may also be interested in...
Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data
ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.
ZymoGenetics' Biotech Disconnect
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out that it's not an easy sell, especially to Wall Street.
ZymoGenetics' Biotech Disconnect
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out that it's not an easy sell, especially to Wall Street.